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Decision uncertainty and value 
of further research: a case-study in fenestrated 
endovascular aneurysm repair for complex 
abdominal aortic aneurysms
Oriana Ciani1,2* , David Epstein3,4, Claire Rothery3, Rod S. Taylor1 and Mark Sculpher3
Abstract 
Background: Fenestrated endovascular aneurysm repair (fEVAR) is a new approach for complex abdominal aortic 
aneurysms, limited to a few specialist centers, with limited evidence base. We developed a cost-effectiveness decision 
model of fEVAR compared to open surgical repair (OSR) to investigate the likely direction of costs and benefits and 
inform further research projects on this technology.
Methods: A systematic review with meta-analysis and a four-state Markov model were used to estimate the cost-
effectiveness of fEVAR versus OSR. We used a recent coverage with evidence development framework to characterize 
the main sources of uncertainty and inform decisions about the type of further research that would be most worth-
while and feasible.
Results: Seven observational comparative studies were identified, of which four presented odds ratios adjusted for 
confounders. The odds ratios for operative mortality varied widely between studies. Assuming a central estimate of 
the odds ratio of 0.54 (95% CI 0.05–6.24), the decision model estimated that the incremental cost per quality adjusted 
life year (QALY) was £74,580/QALY with a probability of 9 and 16% of being cost-effective at standard cost-effective-
ness thresholds of £20,000/QALY and £30,000/QALY, respectively. The Expected Value of Perfect Information over 
10 years at a threshold of £20,000/QALY was £11.2 million. Operative mortality contributed to most of the uncertainty 
in the decision model.
Conclusions: In the case of “maturing technologies”, decision modelling indicates the likely direction of costs and 
benefits and guides the development of further research projects. In our analysis of fEVAR versus OSR, decision 
uncertainty, particularly around operative mortality, might be effectively resolved by a short-term RCT, or possibly a 
well-conducted comparative observational study. Decision makers may consider that a conditional coverage deci-
sion is warranted with assessments required to make this type of recommendation depending on local priorities and 
circumstances.
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Background
Health technology assessment (HTA) agencies are 
charged with providing guidance to practitioners and 
patients based on a systematic and comprehensive 
assessment of the clinical and cost-efectiveness proile 
of health technologies. Assessing medical devices (MDs), 
in particular, raises several challenges which require care-
ful consideration [1]. For a range of reasons, evidence on 
costs and efects relating to medical devices may be lim-
ited [2]. his situation, usually but not exclusively associ-
ated to MD evaluation, leads to a dilemma that typically 
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has proved challenging for HTA and policy makers. Mak-
ing an early decision based on poor evidence carries 
a high risk of error that may be di cult to reverse, but 
delaying a decision until more evidence becomes avail-
able may leave current patients without efective treat-
ment or health systems with ineicient technology.
Fenestrated endovascular repair fEVAR is an example 
of such dilemma. Fenestrated EVAR might be consid-
ered a maturing innovation in the typology of Sculpher 
et al. [3], that is a technology early in its life cycle, usually 
limited to a few specialist centers, with an evidence base 
comprising case series and small RCTs. Decision model-
ling in these situations is unlikely to provide a deinitive 
statement about whether a technology is cost-efective, 
but rather indicate the likely direction of costs and ben-
eits, the circumstances under which the new technology 
might represent good value for money, and to guide the 
development of further research projects [3]. he aim of 
the study is to illustrate this approach through the clinical 
and cost-efectiveness evaluation of fEVAR compared to 
open surgical repair and to estimate  the value of further 
research for the same decision problem.
Abdominal aortic aneurysms (AAAs) occur when the 
main artery in the body develops a balloon-like bulge 
of diameter exceeding 3  cm. he prevalence of AAAs 
in the UK has been estimated at between 1.2 and 7.6% 
in those over 50  years [4]. he beneits of endovascu-
lar aneurysm repair (EVAR) compared to open surgical 
repair (OSR) of AAAs are well established by large multi-
center randomized trials assessing all-cause or aneurysm 
related mortality and postoperative complications [5–7]. 
However, about 15% of AAAs are considered “complex” 
(cAAAs), i.e. aneurysms involving renal or visceral arter-
ies or ‘juxta-renal AAAs’ [8]. Surgical treatment options 
for cAAAs include OSR, usually requiring suprarenal 
aortic cross-clamping, or fEVAR [8–10]. In fEVAR the 
stent-graft fabric extends over the renal arteries, but per-
fusion to these arteries is preserved via accurately placed 
windows (fenestrations) within the stent-graft fabric. 
he fEVAR procedure is more challenging than standard 
EVAR as graft positioning requires both longitudinal and 
rotational alignment of the fenestrations with the target 
vessels [11].
Although a small number of systematic reviews have 
sought to compare eicacy and safety outcomes of fEVAR 
compared to OSR, their conclusions have been limited by 
lack of available robust evidence [12–14]. In particular, 
these reviews noted that there were no randomised con-
trolled trials (RCTs), but there were several registries and 
case series, some of which were large and long-running.
his study evaluates the efectiveness, safety and cost-
efectiveness of fEVAR versus OSR for elective repair of 
cAAA in patients suitable for either procedure. Another 
solution for more complicated aneurysms is branched 
EVAR (bEVAR). he term ‘branched’ refers to the need 
to bridge the gap, created by increased diameter of aorta, 
between the main body of aortic stent graft and tar-
get vessels and not to any actual branch from the graft 
itself [11]. Based on the distinction between bEVAR and 
fEVAR in accordance with the Society of Vascular Sur-
gery reporting standards on thoracic endovascular aortic 
repair [10], branched cAAAs endovascular procedures 
were excluded from this analysis.
Methods
Systematic review and meta-analysis
his updated systematic review was conducted and 
reported according to the Meta-analysis of Observational 
Studies in Epidemiology (MOOSE) reporting guidelines 
[17].
Data sources and search strategy
MEDLINE (via Ovid) was searched for previous system-
atic reviews or meta-analyses of fEVAR for the treat-
ment of cAAAs. We also sought new primary studies 
published since the end date of the literature searches 
of the most recently undertaken systematic review (i.e. 
October 2013) [18] and up to 14th January 2015. A copy 
of the search strategy is available as an Additional ile 1: 
Appendix S1. As this recent review found no RCTs, this 
updated study also includes observational evidence. Two 
reviewers (OC, RST) independently examined titles and 
abstracts of primary studies.
Study selection
Relevant articles were obtained in full, and assessed 
against the inclusion/exclusion criteria described in 
Additional ile  1: Table S1. Any disagreement was 
resolved through discussion.
Data extraction and risk of bias assessment
Details were extracted for each study including: year and 
country of publication, sample size, age and gender dis-
tribution, duration of follow up, anatomical location of 
aneurysms, and details of implant used. Outcomes of 
interest were: operative mortality, late mortality, com-
plications, re-interventions, and resource use during the 
primary admission (i.e. length of stay, operative time, 
blood, and intensive care). Study quality was assessed 
using a modiied list of criteria developed for case series 
[19] and the addition of three criteria for comparative 
studies. Data extraction and risk of bias assessment was 
undertaken by one author (OC) and veriied by another 
(RST).
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Data analysis
Where outcome data were consistently reported, results 
were pooled across studies using Der Simonian and Laird 
random-efects meta-analyses [20]. For operative mortal-
ity, we considered that treatment efects should only be 
pooled where authors made statistical adjustment for rel-
evant confounding factors. For resource use, we consid-
ered that unadjusted diferences were adequate as these 
variables are relatively less inluenced by factors such as 
body mass index, leukocyte count or other biomarkers. 
Moreover, no studies reported between-groups adjusted 
comparison of these measures. Recommendations from 
the Cochrane Handbook for systematic reviews of inter-
ventions were followed to deal with missing data [20]. 
Heterogeneity was quantiied using the  I2 statistic and 
results displayed in a forest plot. All statistical analyses 
were performed using  STATA® 13.1 StataCorp US.
Cost-effectiveness model
his economic evaluation was undertaken and reported 
according to the Consolidated Health Economic Evalua-
tion Reporting Standards (CHEERS) statement [21].
Model structure
A decision analytic model was developed in  Excel®2012 
(Microsoft Corporation, US) to estimate the lifetime cost 
and QALY of each procedure. he structure of the model 
was adapted from a previously published economic 
evaluation of conventional EVAR for AAA repair, using 
essentially the same structure, with parameters estimated 
from the systematic review [22]. he model consists of a 
lead-in period lasting 6 months, during which the cAAA 
repair is undertaken with fEVAR or OSR (Fig. 1). Perio-
perative survivors then enter a long-term three state 
Markov model, which extrapolates costs and outcomes 
over a lifetime horizon using 6-monthly cycles. Dur-
ing each cycle, patients may die of cAAA-related causes, 
such as rupture of the aneurysm, or die of other causes. 
Patients undergo surveillance with an outpatient visit and 
ultrasound every year after endovascular repair and every 
5 years after open repair [23]. Survivors have an ongoing 
risk of re-intervention, e.g. to correct complications of 
the device such as endoleaks which might be detected by 
surveillance. Patients can have only one re-intervention 
per cycle, but can have more than one re-intervention 
over their lifetime. he risk of re-intervention depends 
cAAA = complex abdominal aortic aneurysms
a
patients are at risk of re-intervention in each cycle, with hospital cost and diminished health-related
quality of life 
b
includes deaths related to aneurysm rupture, complications of the grafts, and re-interventions.
Initial cAAA 
repair
Survival after 
cAAA repaira
Aneurysm-
related deathb
Other cause 
death
Fig. 1 Decision analytic model structure. cAAA complex abdominal aortic aneurysms. Patients are at risk of re-intervention in each cycle, with 
hospital cost and diminished health-related quality of life. Includes deaths related to aneurysm rupture, complications of the grafts, and re-interven-
tions
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on initial procedure (OSR or fEVAR) and time from ini-
tial cAAA repair, but is assumed independent between 
cycles. Re-interventions reduce health-related quality of 
life (HRQOL) and incur a hospital cost. Mortality risks 
related to re-intervention are captured in the estimate of 
aneurysm-related deaths.
Perspective of the decision model and inputs required
Health outcomes were expressed in terms of quality-
adjusted life years (QALYs). he perspective adopted was 
that of a publicly funded health system using an explicit 
cost-efectiveness threshold for decision making. he UK 
National Health Service (NHS) [24] is used here as an 
example, using thresholds in the range £20,000-£30,000 
per QALY. he price year was 2016/17, and costs and 
beneits were discounted at an annual rate of 3.5% [24].
Table 1 summarises the main input variables required 
by the decision model and their distributions used to rep-
resent uncertainty. Parameter estimates for the model 
were obtained from the updated systematic literature 
review, personal communication with the device manu-
facturer, and routine UK National Health Service (NHS) 
sources. Where speciic estimates for fEVAR were una-
vailable, the literature on conventional EVAR was consid-
ered. he mean age at which cAAAs repair is undertaken 
was 73  years [25]. Mortality risks for non-AAA cause 
deaths were based on UK male population life tables [26].
Expected value of perfect information
Fenestrated EVAR is a relatively novel technology and 
the evidence relating to its costs and beneits is limited. 
In this regard, further research might be worthwhile if 
it reduces uncertainty and avoids the consequences of 
making a wrong decision about the use of the interven-
tion. he expected value of perfect information (EVPI) 
estimates an upper bound for the value of a new study, 
if it could eliminate all uncertainty about which treat-
ment was more cost-efective at the given cost-per-
QALY threshold. Partial EVPI (EVPPI) is also calculated 
using web-based emulator software [27]. EVPPI enables 
Table 1 Mortality, re-intervention and HRQoL in the cost-effectiveness decision model
AAA Abdominal aortic aneurysms; OSR Open surgical repair; m months; yr years
Mean value used in the 
model
Distribution used in the 
model
Source
Early mortality
 Probability of AAA-related mortality, fEVAR, 0–6 m Pr = 0.026 Beta (43,1627) Additional file 1
 Log-odds ratio, fEVAR vs OSR − 0.61 N (Mean − 0.61, SE 1.22) Meta-analysis of 4 studies 
(adjusted for case-mix)
Late AAA mortality
 Late mortality rate > 6 months–4 years, fEVAR 0.004 Gamma (6, 1/1558) Additional file 1
 Late mortality rate > 4–8 years, fEVAR 0.006 1.5 × 6 months–4 years EVAR-1
 Late mortality rate > 8 years, fEVAR 0.008 2 × 6 months-4 years EVAR-1
 Log Hazard ratio > 6 months-4 years, fEVAR vs OSR 0.38 N (0.38, 0.48) EVAR-1
 Log Hazard ratio > 4–8 years, fEVAR vs OSR 1.13 N (1.13, 0.57) EVAR-1
 Log Hazard ratio > 8 years, fEVAR vs OSR 1.76 N (1.76, 0.63) EVAR-1
Re-interventions 0–6 months
 Probability, fEVAR 0.068 Beta (81, 1117) Additional file 1
 Log odds ratio, fEVAR vs OSR − 0.87 N (− 0.87, 0.24) Meta-analysis of 3 studies 
(unadjusted for case-mix)
Re-interventions > 6 months
 Re-intervention rate > 6 months-4 years, fEVAR 0.087 Gamma (132, 1/1507) Additional file 1
 Re-intervention rate > 4–8 years, fEVAR As > 6 months–4 years Assumption
 Re-intervention rate > 8 years, fEVAR As > 6 months–4 years Assumption
 Log Hazard ratio > 6 months–4 years, fEVAR vs OSR 1.84 N (1.84, 0.35) Additional file 1
 Log Hazard ratio > 4–8 years, fEVAR vs OSR 0.47 N (0.47, 0.34) EVAR-1
 Log Hazard ratio > 8 years, fEVAR vs OSR 0.47 N (0.47, 0.34) EVAR-1
Health related quality of life, EQ-5D index
 After AAA repair, baseline 0.804 N (0.804, 0.021) EVAR-1
 Decrement after OSR 0-6 m − 0.060 N (− 0.060, 0.017) EVAR-1
 Decrement in the 6 months following a re-intervention − 0.060 N (− 0.060, 0.026) EVAR-1
 Decrement in the 6 months before death − 0.149 N (− 0.149, 0.017) EVAR-1
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identiication of those parameters that contribute par-
ticularly highly to decision uncertainty.
A decision timeframe of 10 years is used, to allow for 
obsolescence and product innovation by competing tech-
nologies. We assume that 1782 cAAA patients would be 
eligible for repair each year in the UK, based on German 
health insurance data [25] adjusted for UK population 
size. Net population beneit was calculated at cost-efec-
tiveness thresholds used in the UK.
Decision uncertainty was estimated through probabil-
istic sensitivity analysis using 1000 Monte-Carlo simula-
tions of the model [28].
Decision making and the value of further research
We used a recently developed framework to character-
ize the sources of uncertainty and to identify the most 
appropriate decision option for fEVAR given the avail-
able evidence [15, 29]. Four decision options were con-
sidered: accept fEVAR for immediate and general use in 
the national heath service in indicated patients (accept 
fEVAR), reject fEVAR (i.e. accept OSR), accept fEVAR 
provisionally but conditioned upon the collection of 
further evidence (accept with research, AWR), or reject 
fEVAR for general use until further evidence becomes 
available (only in research, OIR).
Results
Systematic review and meta-analysis
he updated systematic review study selection process is 
illustrated in Fig. 2. A total of 22 studies involving 1641 
fEVAR patients were included (see Additional ile  1: 
Appendix S2 for list of included studies). Whilst we did 
not ind any randomised trials comparing fEVAR and 
OSR, we did include seven comparative observational 
studies, reporting outcomes for both fEVAR and OSR 
patients [30–36].
Study characteristics
A summary of the study and patient population charac-
teristics and the interventions is reported in Additional 
ile  1: Table  S2. Study sample sizes were small, with a 
median of 78 fEVAR treated patients, a median patient 
age of 74 years and a median follow-up of 18.4 months. 
All studies showed high to moderate risk of bias as 
reported in Additional ile 1: Table S3.
Relative risk of operative mortality
Seven observational studies compared perioperative [30, 
36] or 30-day [31–35] mortality between fEVAR and OSR 
(Additional ile  1: Table  S4). he pooled odds ratio for 
mortality across all seven studies was 0.60 (95% CI 0.23–
1.60, p = 0.014) (Additional ile  1: Figure  S1). However, 
Fig. 2 Flow diagram—study selection process
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there was a high degree of heterogeneity between studies 
 (I2 statistic: 62.6%, p = 0.014).
Risk of bias for estimate of relative risk of operative 
mortality
In a context of poor available evidence, it is even more 
important to explore the heterogeneity and evaluate the 
risk of bias in order to reliably use the information for 
decision-making purposes. One source of heterogeneity 
was the method used by the study to account for possible 
confounding. hree studies did not make any adjustment 
for confounding variables [31–33]. Of the four that took 
account of confounding variables in some way, one used 
multivariate regression [35], one used propensity score 
matching [34], and two used a published risk score [37] to 
estimate what operative mortality hypothetically would 
have been in the fEVAR patients had they had undergone 
open repair [30, 36]. More on the risk of bias assessment 
performed for estimate of relative risk of operative mor-
tality is reported in Additional ile 1: Appendix S3.
Relative risk of operative mortality stratified by study 
methodology
To further explore the heterogeneity, we stratiied 
the pooled estimate of efect size according to the 
methodology in the study employed to adjust for con-
founders. he Raux study [34] (propensity score match-
ing) found an OR of 5.1 (95% CI 1.1–24). he Tsilimparis 
study [35] (multivariate regression) found an OR of 
0.19 (95% CI 0.04–0.83). he two studies that used the 
V-POSSUM risk score 26,32 found a pooled OR of 0.37 
(95% CI 0.20–0.69). he remaining studies that did not 
adjust for confounders found a pooled OR of 0.98 (95% 
CI 0.26–3.7).
Relative risk of operative mortality used as input to the 
decision model
he pooled estimate of the odds ratio over the four 
studies that performed some form of risk adjust-
ment is 0.54 (95% CI 0.16–1.88) (Fig.  3). he decision 
model uses the OR estimate of 0.54 as the base-case 
(log(OR) = μ = − 0.61, SE(μ) = 0.644). However, this SE 
from random-efects meta-analysis does not take account 
of the full distribution of efect sizes across the hetero-
geneous studies [38]. In order to make predictions about 
the likely efect size that might occur in a future new 
study or in the general practice use, we considered the 
estimate of τ2 from the four adjusted studies in the ran-
dom-efects meta-analysis [30, 34–36] (τ2 = 1.15). his 
Fig. 3 Pooled odds ratio of adjusted operative mortality fEVAR vs OSR
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suggests a mean and conidence interval for a prediction 
for a new study of 0.54 (95% CI 0.05–6.24).
Baseline risk of operative mortality used as input to the 
decision model
Twenty-two studies reported operative mortality after 
fEVAR, with 43 deaths in 1670 patients (mean rate 2.6%) 
[30–36, 39–53]. However, there was considerable het-
erogeneity, with operative mortality varying from 0% to 
9.5% (Additional ile 1: Table S5). Analysis of UK national 
hospital episode statistics indicates the mean opera-
tive mortality after OSR in clinical practice, as opposed 
to selected case series in specialist centres, is 14%, with 
considerable heterogeneity [54]. In the model, we use the 
mean operative mortality after fEVAR from the system-
atic review as the probability of AAA death during the 
irst model cycle in the base-case and vary this from 0.5% 
to 9.5% in sensitivity analyses, assuming the baseline rate 
and the relative risk are independent.
Late aneurysm-related mortality
One study included in the review compared late aneu-
rysm related mortality with about 1  year of follow-up 
between fEVAR and OSR [31] and found no late AAA-
related deaths in either group.
hirteen studies [31, 32, 36, 39–42, 44–46, 49, 51, 52] 
reported late AAA mortality after fEVAR. he overall 
rate of late AAA mortality was 6 deaths in 1558 patient-
years (i.e. an average of 0.004 late AAA deaths per per-
son-year) although 10 studies [36, 39–47] reported no 
late AAA-related deaths (Additional ile 1: Table S5). he 
decision model assumes this 0.004 rate of late AAA mor-
tality after fEVAR from > 6  months to 4  years (as found 
by this review), but that this rate would increase by 50% 
between 4  years and 8  years and doubles after 8  years 
(as found after conventional EVAR by the EVAR-1 trial 
[22]). Furthermore, the base-case model assumes relative 
risk of late AAA mortality would be greater after fEVAR 
compared with OSR (as found by the EVAR-1 trial [22]). 
Sensitivity analyses explore a scenario where the rate of 
late AAA mortality does not increase over time and is 
the same as OSR (as found by Chisci et al. [31] study at 
1 year) over the patient’s lifetime.
Early and late re-interventions
Eleven studies reported a total of 81 early re-interven-
tions (in-hospital or 30-day) in 1198 patients after fEVAR, 
an average probability of 0.07 [30, 31, 34, 39, 42, 43, 47, 
50, 52]. hree studies compared the risk of early (in-hos-
pital or 30-day) re-interventions for fEVAR compared to 
open repair [30, 31, 35]. All found more re-interventions 
after open repair with a pooled OR across the three trials 
of 0.42 (95% CI 0.26–0.68) (Additional ile 1: Figure S4). 
hese results were not adjusted for case-mix. Eleven 
studies reported a total of 132 late re-interventions in 
1507 patient-years of follow-up after fEVAR, an average 
rate of 8.8 per 100 patient-years. No trial reported late re-
interventions after open repair [32, 36, 41, 47, 48, 51, 52].
As the studies did not provide suicient information 
on how the re-interventions rate might change over time, 
the decision model uses the rates of early re-interven-
tions from the literature review, and the relative risk of 
late re-intervention (fEVAR vs OSR) from the EVAR-1 
RCT [22] that compared EVAR versus open repair for 
conventional AAA, which was 6.29 (95% CI 3.09–12.78) 
from 6 months to 4 years, 1.60 (95% CI 0.81–3.15) from 4 
to 8 years, and 1.51 (1.71–3.19) after 8 years [55].
Resource consumption
Five studies provided comparative information on one 
or more healthcare resource use outcomes (Table  2, 
Table  3) [30–33, 35]. here was considerable heteroge-
neity across most of the resource use data. he decision 
model uses the average estimates of procedure resource 
use (i.e. length of stay, operating theatre, blood units and 
Intensive Care Unit stay) costed at UK prices in 2016/17 
[55, 56]. he list price of the fEVAR device was £16,500 
including extra stent parts and accessories (personal 
communication with Cook Medical, at 2015 prices). Sen-
sitivity analyses were conducted by varying the price of 
the stent to relect possible discounts. A reduction in 
cost might also be achieved if use of fEVAR was associ-
ated with lower length of stay or less use of other hospital 
resources, or if surveillance and re-interventions could be 
accurately targeted at patients with higher risk of compli-
cations. Other unit costs associated with the index pro-
cedure are given in Table  3. he cost of a AAA-related 
re-intervention was taken as £8670 (SE 831) [55].
Health-related quality of life
No study reported health related quality of life (HRQOL) 
after fEVAR or OSR. he EVAR-1 trial found that 
HRQOL was better after conventional EVAR than OSR 
for the irst 6  months (mean diference in EQ-5D-3L 
0.060, SE(0.017)) but there was no diference by 1  year 
[22]. HRQOL is considerably diminished in the 6 months 
after a re-intervention and in the 6  months preceding 
death [57].
Complications
Peri-operative complications were poorly and heteroge-
neously reported, especially after open repair. he studies 
did not give a clear indication of the seriousness of the 
complication or its duration. herefore complications 
were not explicitly costed or associated with QALYs in 
the model. However, some measure of their impact is 
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included in the cost-efectiveness analysis, because seri-
ous complications and adverse events during the surgical 
procedure and hospital stay will be relected in HRQOL, 
length of stay, operative theatre time, blood use, and use 
of ICU.
Cost-effectiveness model
he mean diference in lifetime cost between fEVAR and 
OSR was £15,606 (95% CI 8390–22,512), and the lifetime 
diference in QALY was 0.209 (95% CI − 0.124–1.311), 
(Table  4, Additional ile  1: Figure  S2). he incremental 
cost-per-QALY is estimated to be £74,579/QALY with a 
probability of 0.090 of being cost-efective at a threshold 
Table 2 Resource consumption in fEVAR and OSR patients
ICU intensive care unit; WMD weighted mean difference
a Median instead of mean
b 450 ml blood per unit
c IQR = 1.35*SD as in normal distribution
fEVAR OSR Pooled WMD (95% CI)
N Mean (SD) N Mean (SD)
Length of stay (days)
 Moore 2006 16 14.8 (17.3) 29 13 (8.0) − 4.83 (− 7.33 to − 2.32)  I2 = 87.4% p < 0.0001
 Donas 2012 29 3.5 (1.1) 31 7.2 (3.2)
 Canavati  2013c 53 7.0 (3.3) 54 12 (9.6)
 Tsilimparis 2013 246 3.0 (4.3) 1091 10 (9.6)
Operative time (min)
 Moore 2006 16 268 (113.0) 29 205 (196.0) 38.72 (− 79.00 to 156.44)  I2 = 98.6% p < 0.0001
 Chisci 2009* 52 266 (94) 61 150 (38)
 Donas 2012 29 290 (122.0) 31 204.00
 Canavati 2013 53 300 (88.9) 54 235 (66.7)
 Tsilimparis 2013 246 175.7 (101.8) 1091 260.57 (109.0)
Blood unit  transfusedb
 Moore 2006 16 4.4 (5.8) 29 6.5 (5.8) − 2.41 (− 2.72 to − 2.11)  I2 = 16.1% p = 0.311
 Chisci  2009ac 52 1.12 (0.95) 61 3.45 (1.24)
 Donas 2012 29 0.2 31 3.2 (1.2)
 Canavati  2013ac 53 2.8 (2.2) 54 4.4 (3.1)
 Tsilimparis 2013 246 0.5 (1.9) 1091 3.1 (4.0)
ICU stay (days)
 Moore 2006 16 4 (8.5) 29 1.7 (2.7) − 0.88 (− 6.8 to 5.04)  I2 = 79.2% p = 0.028
 Canavati  2013ac 53 0.58 (7.8) 54 4.33 (26.7)
Table 3 Costs of procedures in the economic model
Costs inflated to 2016/17 prices using hospital pay and prices index [56]
WMD weighted mean difference, OSR open surgical repair, fEVAR fenestrated endovascular repair
Natural units, OSR Difference fEVAR-OSR Unit cost (£) Mean cost open Mean cost fEVAR
Resource Mean of studies from meta-
analysis
Pooled WMD from meta-analysis 
(Table 2)
53
Length of stay (days) 10 − 4.83 353 2593 1352
Operative time (mins) 251 38.72 19.58 4421 5102
Blood units (450 ml) 3.25 − 2.41 144 454 118
ICU stay (days) 3.41 − 0.88 1178 4059 3012
Cost of device (£) 312 16,502
Other consumables 246 516
Total 13,529 27,658
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Table 4 Mean costs and QALYs estimated by the model and sensitivity analyses
OSR open surgical repair, fEVAR fenestrated endovascular aneurysm repair, ICER incremental cost effectiveness ratio, QALY quality-adjusted life years, Pr(X) probability that fEVAR is cost-effective at threshold of X(£), 
Dominated fEVAR had greater cost and lower health benefit
Scenario 2: Odds ratio (OR) of operative mortality favours OSR
Scenario 3: OR of operative mortality is more favourable to fEVAR than the base-case
Scenario 4: Greater base-line risk of operative mortality
Scenario 5: Lower base-line risk of operative mortality
Scenario 6: No difference in late-aneurysm related deaths between groups
Scenario 7: No difference in late re-interventions between groups
Scenario 8: Lower price of endovascular device
Cost OSR QALY OSR Cost fEVAR QALY fEVAR Difference in cost 95% CI Difference in QALY 95% CI ICER p (20 k) p (30 k)
Base-case 16,067 4.333 31,673 4.542 15,606 8391 22,512 0.209 − 0.124 1.311 74,580 0.090 0.158
Model2 16,246 4.626 31,604 4.544 15,358 8126 22,902 − 0.082 − 0.167 0.090 Dominated 0.001 0.003
Model3 15,860 4.017 31,694 4.554 15,834 8383 23,611 0.537 − 0.072 1.944 29,498 0.269 0.401
Model4 15,801 3.923 31,648 4.295 15,848 8467 23,859 0.372 − 0.318 1.707 42,584 0.224 0.318
Model5 16,194 4.525 31,762 4.615 15,567 8126 23,379 0.090 − 0.083 0.612 173,452 0.019 0.046
Model6 16,032 4.303 31,876 4.547 15,843 8438 23,193 0.243 − 0.071 1.136 65,154 0.077 0.165
Model7 18,292 4.353 31,665 4.548 13,373 6089 20,803 0.196 − 0.118 1.101 68,348 0.100 0.169
Model8 16,047 4.344 22,948 4.545 6901 − 804 14,238 0.201 − 0.123 1.308 34,373 0.249 0.330
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of £20,000 per QALY, and a probability of 0.158 at 
£30,000 per QALY [24]. Almost all of the additional cost 
is incurred in the price of the fEVAR device (Additional 
ile 1: Figure S3).
External validation of model results
he predicted overall survival in the model after OSR at 
5 years is 58% (Additional ile 1: Figure S2), the same as 
reported from a study linking Hospital Episode Statistics 
to national mortality records in the UK [54].
Sensitivity analyses
he following univariate sensitivity analyses were 
conducted:
1. Base-case;
2. High relative risk of operative mortality (OR 5.1, 95% 
CI 1.10–24) [34];
3. Low relative risk of operative mortality (OR 0.19, 95% 
CI 0.05–0.83) [35];
4. High baseline risk of operative mortality after fEVAR 
of 9.5% [34];
5. Low baseline risk of operative mortality after fEVAR 
of 1% [35];
6. No diference in late (> 30  day) mortality between 
fEVAR and open repair [31];
7. No diference in late re-interventions between fEVAR 
and open repair;
8. Price of fEVAR device of £7500.
he sensitivity analyses show the circumstances under 
which fEVAR plausibly might be cost-efective (Table 4). 
If the OR of operative mortality were that observed in 
the most favourable study, assuming that baseline risk 
remains unchanged, then fEVAR comes close to the 
£30,000/QALY threshold. fEVAR would also be close to 
this threshold if the cost of the device were £7500, rather 
than £16,500.
Expected value of perfect information
he EVPI over 10  years at a threshold of £20,000 per 
QALY was £11.2 million. EVPPI analysis showed that 
92% of this value could be attributed to the two operative 
mortality parameters (baseline and odds ratio), and the 
remainder to the cost of the procedure.
The value of further research
Under the base-case model, fEVAR is unlikely to be cost-
efective. his does not necessarily mean that it should 
be rejected, if further evidence might lead to diferent 
conclusions. Claxton et  al. provide a checklist of the 
sequence of assessments that would be required for an 
HTA body considering whether further research should 
be mandated [58]. We provide a structured discussion of 
the issues as they might apply to fEVAR given the results 
of this study. However, each decision maker would need 
to review and interpret the data as they apply to health 
services in their jurisdiction.
Is the technology expected to be cost-effective?
his would depend on the decision criteria used (e.g. the 
cost-per-QALY threshold) as well as the decision-maker’s 
interpretation of the appropriate inputs for the model. 
We assume it is likely not cost-efective on current evi-
dence and from the perspective of the NHS in the UK 
[24].
Are there significant irrecoverable costs?
Implementing FEVAR would not require signiicant irre-
coverable costs in NHS infrastructure, if most of the up-
front investment in operating facilities and interventional 
radiography has already been made. However, on-going 
training for surgical teams would be required, and the 
procedure is of course irreversible for individual patients.
Does more research seem worthwhile?
here are no RCTs, there is considerable decision uncer-
tainty from the model, and more research might plausi-
bly reduce that uncertainty. Some assessment is therefore 
needed of the type of evidence and whether it can be 
conducted without approval.
Is the research possible with (without) approval?
Generally, most types of research are possible without 
approval, including RCTs. However, the patient popula-
tion who might potentially beneit from fEVAR is small 
and hence population EVPI is only about £11 million at 
a threshold of £20,000/QALY in the UK. his means a 
large-scale, expensive, lengthy RCT would not be cost-
efective. Nevertheless, in our EVPPI analysis, most of 
the uncertainty was around operative mortality, which 
might indicate that a RCT with short follow-up, or even 
a well-designed observational study would provide sui-
cient evidence for deinitive approval or rejection. hese 
factors would indicate OIR would be an appropriate 
decision.
Will other sources of uncertainty resolve over time?
A further source of uncertainty, which has not been 
relected in our analysis, is the possibility of a learning 
curve for fEVAR. Fully understanding the learning curve 
might require the technology to be in widespread use. 
If this knowledge is important to the decision maker, it 
would argue in favour of AWR even though the technol-
ogy is not thought to be cost-efective on current evi-
dence. However, a recent analysis based on over 40,000 
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patients administrative data from year 2006 to 2013 in 
Germany using hierarchical regression models showed 
the learning curve for fEVAR on in-hospital mortality 
and length of stay is actually negligible [25].
Discussion
In this study we investigated the clinical and cost-efec-
tiveness evaluation of fEVAR compared to open surgical 
repair as an example of a technology with limited evi-
dence base and difusion across a few specialized sites 
where the decision modelling is intended to identify the 
circumstances under which the new technology might 
represent a worthwhile investment and to inform future 
evidence generation projects.
his updated systematic review and meta-analysis 
found no RCTs that compared fEVAR and OSR. A recent 
NIHR funded project has updated a similar review up to 
March 2017 conirming no RCTs is available to date and 
the most recent comparative FEVAR vs OSR study was 
Raux et  al. 2014 as per our results [59]. Seven observa-
tional studies compared these procedures, with varying 
methodological quality and substantial heterogeneity 
across all the outcomes.
Decision-makers responsible for setting prices of medi-
cal technologies or deciding re-imbursement policy 
need to make an assessment of whether the technol-
ogy appears cost-efective on current evidence. In cases 
where the evidence base is highly uncertain and of poor 
methodological quality, decision makers may also need to 
assess what type of further research might be of value.
he usefulness of a decision model in these cases is 
not to make a deinitive statement about cost-efective-
ness, but rather to serve as a framework to organise the 
available data, identify the most important gaps in the 
evidence, and assess the plausible circumstances under 
which the technology might be cost-efective. In the 
fEVAR case, we were reliant on non-randomised com-
parative studies that are prone to bias and confounding. 
We assessed the risk of bias and focused our meta-analy-
sis on four comparative studies that were judged to have 
performed adequate adjustment. hese data were used 
in the model to estimate short-term outcomes. here 
was little data on late outcomes after fEVAR, particu-
larly late AAA-deaths and complications. Long-term data 
from conventional endovascular devices clearly shows a 
greater rate of complications and re-interventions than 
after open repair, though it is di cult to know how gen-
eralizable these data are to fEVAR.
Using these data as base-case inputs, the model esti-
mated that fEVAR is associated with greater survival 
and QALYs over a patient’s lifetime compared with OSR. 
However, the high acquisition cost of the device means 
that the cost of fEVAR considerably exceeds OSR. he 
EVAR-1 trial [22] showed that the frequency of re-inter-
ventions over the medium and long term is also likely to 
be greater under endovascular repair, though this is not 
a decisive driver of overall cost in the model. he overall 
treatment costs make fEVAR not cost-efective at conven-
tional National Institute for Health and Care Excellence 
(NICE) thresholds, with an ICER exceeding £74,000/
QALY. he cost-efectiveness threshold seeks to relect 
the magnitude of health that other types of patients forgo 
when additional costs are incurred on a new technol-
ogy rather than treatments from which they will beneit 
[24]. NICE’s threshold range of £20,000 to £30,000 has 
no empirical link to such opportunity costs, and recent 
research estimates the threshold to be lower at around 
£13,000 per QALY [60]. his would suggest that fEVAR 
is not cost-efective in the UK NHS based on current evi-
dence. he model takes into account resource consump-
tion estimates from the literature review of international 
studies, hence transferability of the model to other juris-
dictions is possible, subject to availability of costs data 
from other countries. Criteria for decision-making rarely 
rely on a formal cost-efectiveness threshold outside UK 
[61], hence each decision maker would need to review 
and interpret these results in the context of the health 
systems in place in their jurisdiction. Sensitivity analy-
ses showed that fEVAR would be close to being cost-
efective at the upper range of NICE’s threshold if the OR 
of operative mortality were 0.19, as estimated by one of 
the studies [35]. fEVAR would also be cost-efective at 
this threshold if the price of the stent was about £7500 
instead of £16,500. High-volume centres may already be 
able to negotiate discounts with suppliers, although these 
are commercially conidential.
Expected value of further information analysis showed 
that the population EVPI is not especially great, because 
this is a specialist procedure with a limited target popu-
lation. his would increase if one was willing to accept 
that research is a global public good that would beneit 
patients worldwide [62]. Nevertheless, most of the deci-
sion uncertainty is around operative mortality. his might 
be efectively resolved by a short-term RCT, or possibly 
a well-conducted comparative observational study [59]. 
Decision makers may consider that a conditional cover-
age decision is warranted with assessments required to 
make this type of recommendation depending on local 
priorities and circumstances.
he model we have used in this paper is very sim-
ple, as we have tried to remain faithful to the evidence. 
here may be several other considerations which would 
warrant further evidence collection. For example, the 
model assumes the OR of operative mortality is inde-
pendent of the base-line risk. In practice there may 
be sub-group efects. he literature review does not 
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discriminate between male and female patients. here 
is some evidence from conventional EVAR that out-
comes for females are diferent, given the diferent ana-
tomical morphology. Over 90% of incident AAA patients 
between 55 and 84 years age are male, and outcomes and 
costs in women are insuiciently described in the litera-
ture [63]. here are some other important complications 
arising from cAAA repair, such as renal impairment or 
spinal cord injury that have not been taken into account 
in the model [8].
Nevertheless, the situation described in this study is 
typical of a medical-device procedure whose adoption 
and difusion occur without strong clinical evidence 
supporting its marketing authorization, particularly 
in Europe. Based on current evidence, our model pre-
dicts that at conventional decision-making thresholds in 
the UK, fEVAR is not cost-efective and more research 
might plausibly reduce the decision uncertainty from the 
model. Staged approaches to evidence collection [64] or 
innovative and structured decision-making processes 
[16] linking the gathering of additional information with 
policies on approval for reimbursement around devices-
related surgical procedures are recommended.
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